Your browser doesn't support javascript.
loading
Post COVID Vaccination (COVAXIN™ -BB152 V) Pauci-immune Crescentic Glomerulonephritis.
Bansal, Shyam B; Rana, Abhyuday S; Manhas, Neha; Rana, Alka.
Afiliación
  • Bansal SB; Department of Nephrology and Renal Transplant Medicine, Medanta -The Medicity, Gurugram, India.
  • Rana AS; Department of Nephrology and Renal Transplant Medicine, Medanta -The Medicity, Gurugram, India.
  • Manhas N; Department of Nephrology and Renal Transplant Medicine, Medanta -The Medicity, Gurugram, India.
  • Rana A; Department of Pathology and Laboratory Medicine, Medanta -The Medicity, Gurugram, India.
Indian J Nephrol ; 32(5): 495-497, 2022.
Article en En | MEDLINE | ID: mdl-36568599
ABSTRACT
Coronavirus disease 2019 (COVID-19) pandemic is responsible for widespread morbidity and mortality. The vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, the cause of the COVID-19 pandemic, is currently ongoing across the globe. Rapid vaccination is of paramount importance to mitigate this pandemic. Although considered safe in general, these vaccines have their share of rare adverse events. We report a case of antineutrophil cytoplasmic antibody (ANCA)-associated pauci-immune crescentic glomerulonephritis 15 days post 2nd dose of a killed COVID-19 (COVAXIN™ -BB152 V) vaccine. We hypothesize that vaccination triggered a systemic immune response in a susceptible patient to develop ANCA-associated vasculitis (AAV), leading to rapidly progressive glomerulonephritis (RPGN).
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Indian J Nephrol Año: 2022 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Indian J Nephrol Año: 2022 Tipo del documento: Article País de afiliación: India